Development and validation of liquid chromatography–tandem mass spectrometric method for simultaneous determination of fosinopril and its active metabolite fosinoprilat in human plasma

Cui, Shuangjin; Fěng, Fang; Ma, Ming; Han, Lijun; Chen, Yun

doi:10.1016/j.jchromb.2007.04.019

Cited by 9 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HPLC-MS/MS assays were developed to determine the concentrations of the ACEI active metabolites enalaprilat, ramiprilat, perindoprilat, moexiprilat, and fosinoprilat based on previously published methods with some modifications 29–33 . The HPLC-MS/MS system consists of a Shimadzu HPLC system and an Applied Biosystems API 4000 QTRAP ® mass spectrometer.…”

Section: Methodsmentioning

confidence: 99%

CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors

et al. 2015

View full text Add to dashboard Cite

The aim of the study was to determine the effect of carboxylesterase 1 (CES1) genetic variation on the activation of angiotensin-converting enzyme inhibitor (ACEI) prodrugs. In vitro incubation study of human liver, intestine and kidney s9 fractions demonstrated that the ACEI prodrugs enalapril, ramipril, perindopril, moexipril and fosinopril are selectively activated by CES1 in the liver. The impact of CES1/CES1VAR and CES1P1/CES1P1VAR genotypes and diplotypes on CES1 expression and activity on enalapril activation was investigated in 102 normal human liver samples. Neither the genotypes nor the diplotypes affected hepatic CES1 expression and activity. Moreover, among several CES1 nonsynonymous variants studied in transfected cell lines, the G143E (rs71647871) was a loss-of-function variant for the activation of all ACEIs tested. The CES1 activity on enalapril activation in human livers with the 143G/E genotype was approximately one-third of that carrying the 143G/G. Thus, some functional CES1 genetic variants (for example, G143E) may impair ACEI activation, and consequently affect therapeutic outcomes of ACEI prodrugs.

show abstract

Section: Methodsmentioning

confidence: 99%

CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The coefficient of correlation ( r ) ranged from 0.9975 to 0.9995 (average r = 0.9993) for the linearity studies carried out for FPD. The LLOQ concentration for FPD was 0.50 ng/ml, hence the method proved to be very sensitive as compared with the other reported methods (Tu, Brennan, Stouffer, & Eckelman, 1990; Ford et al, 1995; Greenbaum et al, 2000; Jemal, Huang, Mao, Whigan, & Schuster, 2000; Jemal & Mulvana, 2000; Jancic et al, 2005; Cui, Feng, Ma, Liu, & Chen, 2007; Xue et al, 2015).…”

Section: Resultsmentioning

confidence: 80%

“…Hence, a technique which would extract maximum FPD from the bound plasma proteins was required. Liquid–liquid extraction technique has already been utilized by Cui, Feng, Ma, Liu, and Chen (2007) for the determination of Fosinopril and FPD from human plasma. Therefore, experiments using protein precipitation and SPE techniques were carried out by the authors to extract FPD from human plasma.…”

Section: Resultsmentioning

confidence: 99%

“…Bioanalysis of FPD from human plasma using an HPLC method with UV detection at 220 nm has also been reported (Jancic, Ivanovic, Medenica, Malenovic, & Dimkovic, 2005). Cui, Feng, Ma, Liu, and Chen (2007) determined Fosinopril and FPD simultaneously from human plasma by LC–MS/MS. In this method, liquid–liquid extraction technique was used for the sample preparation and Zaleplon was used as the internal standard (IS).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A sensitive and efficient LC–MS/MS method for the bioanalysis of fosinopril diacid from human plasma and its application for a bioequivalence study in humans

Bhende

Varanasi²,

Abbulu³

2021

Biomedical Chromatography

View full text Add to dashboard Cite

Fosinopril diacid is an angiotensin converting enzyme inhibitor with efficient antihypertensive action. It is an active metabolic product formed in the body from hydrolysis of its prodrug Fosinopril. A sensitive, rapid method with high recovery for Fosinopril diacid from human plasma was developed. Solid‐phase extraction technique employing Waters Oasis SPE cartridges gave clean samples with very high recovery of 97%. The analyte along with its internal standard (Benazepril hydrochloride) were chromatographed on an XTerra RP8 column (4.6 × 50 mm, 5 μm) using methanol–ammonium acetate buffer (10 mm; 90:10, v/v) as the mobile phase. A triple quadrupole mass spectrometer equipped with electrospray ionization source operated in the negative ion mode was used for detection. Multiple reaction monitoring scan mode was used for monitoring the transitions from m/z 434.00 → 237.15 for Fosinopril diacid and m/z 423.10 → 174.00 for Benazepril hydrochloride. Beer–Lambert’s law was obeyed in the range of 0.50–1,500.00 ng/ml (r = 0.9993). The stability of the drugs in human plasma and in stock solution was proved by performing stability tests as per US Food and Drug Administration guidelines. The method was successfully applied for a bioequivalence study of Fosinopril diacid in 36 healthy, adult, male volunteers under fasting conditions.

show abstract

“…A number of reports have described bioanalytical LC-MS assays for the determination of BNZ, FOS and CAP either individually (Chik et al, 2014;Rezende et al, 2007;Salem, Saif, Jmeian, & Al Tamimi, 2005;Vancea et al, 2009) or each drug in the presence of its metabolite (Cui, Feng, Ma, Liu, & Chen, 2007;Jemal & Mulvana, 2000;Xiao, Chen, Yao, & Cheng, 2005;Xue et al, 2015) or BNZ in the presence of other drugs such as gliclazide and valsartan (Hu et al, 2009). HCT was determined simultaneously with lisinopril by LC-MS method (Shah, Shah, Shah, Sanyal, & Shrivastav, 2017).…”

Section: Introductionmentioning

confidence: 99%

Simultaneous ultraperformance liquid chromatography/tandem mass spectrometry determination of four antihypertensive drugs in human plasma using hydrophilic–lipophilic balanced reversed‐phase sorbents sample preparation protocol

Mahrouse

2018

Biomedical Chromatography

View full text Add to dashboard Cite

Therapeutic drug monitoring of angiotensin-converting enzyme inhibitors has a great impact on blood pressure control in patients with heart failure and hepatic and renal impairment. To provide an efficient tool for drug assessment in plasma, a UPLC-MS/MS method was developed for simultaneous determination of benazepril hydrochloride, fosinopril sodium, captopril and hydrochlorothiazide in human plasma samples. Solid phase extraction was applied for sample preparation using OASIS hydrophilic-lipophilic balanced reversed-phase sorbents cartridges. Chromatographic separation was performed using an Agilent SB-C column and methanol-0.1% formic acid in water (95:5, v/v) as mobile phase, at flow rate 0.3 mL/min. Detection was accomplished using a tandem mass spectrometer. The method was validated according to US Food and Drug Administration guidelines. It showed good linearity over concentration ranges 5-400 ng/mL for benazepril hydrochloride, fosinopril sodium and hydrochlorothiazide and 100-3500 ng/mL for captopril. CV% values were <13.92% whereas the mean accuracy ranged from 94.50 to 113.82% for quality control samples and their extraction recoveries ranged from 90.60 to 99.38%. In conclusion, the present study revealed method selectivity and sensitivity; it can be applied for estimation of angiotensin converting enzyme inhibitors and hydrochlorothiazide in human plasma for dose adjustment and therapeutic drug monitoring.

show abstract

Development and validation of liquid chromatography–tandem mass spectrometric method for simultaneous determination of fosinopril and its active metabolite fosinoprilat in human plasma

Cited by 9 publications

References 17 publications

CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors

CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors

A sensitive and efficient LC–MS/MS method for the bioanalysis of fosinopril diacid from human plasma and its application for a bioequivalence study in humans

Simultaneous ultraperformance liquid chromatography/tandem mass spectrometry determination of four antihypertensive drugs in human plasma using hydrophilic–lipophilic balanced reversed‐phase sorbents sample preparation protocol

Contact Info

Product

Resources

About